ERBB2 and neoplasm: In addition, no statistically significant difference was seen between HER2-positive tumors in terms of many other clinicopathological parameters such as lymph node metastasis (p = 0.410), histological tumor type (p = 0.177), lymphatic vascular invasion (p = 0.179), and tumor stage (p = 0.821).